Why Investors Should Like BioNTech's Latest Deal With Gilead

·4-min read

BioNTech (NASDAQ: BNTX) has begun to spend some of the cash generated by its COVID-19 vaccine. The German drugmaker recently announced an agreement with Gilead Sciences (NASDAQ: GILD) to acquire a research program and a manufacturing site. In this Motley Fool Live video recorded on July 21, 2021, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss what investors should like about BioNTech's deal with Gilead.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting